Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. - Wikidata - wikimedia - TriplyDB

Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.

Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.

http://www.wikidata.org/entity/Q37151600

about

A Multifunctional Micellar Nanoplatform with pH-Triggered Cell Penetration and Nuclear Targeting for Effective Cancer Therapy and Inhibition to Lung Metastasis.Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer.

P2860

Q48243896-8A27EF2E-5D04-4BAB-9B86-D671E44C5093 Q50675888-BCF112C6-F3EF-4D19-A8B0-235F8A0C9F75

P2860

Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.

http://www.wikidata.org/entity/Q37151600

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@en

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@nl

type

label

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@en

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@nl

prefLabel

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@en

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@nl

P1433

Q37151600-58B4EF35-635F-419E-A179-AC4D75203948

P1476

Q37151600-00E61F24-9843-4EB2-8F15-E9016CB1E81C

P2093

Q37151600-2F599E22-1A58-4016-A39F-9EFDADBCCB02

Q37151600-338AB15B-DD91-40CF-A849-849819D2E47C

Q37151600-34C3A568-0FF5-4C87-9FD4-D5B324D45809

Q37151600-80CCEA79-B610-45F7-9671-8E9FCEE51292

Q37151600-8F391FFE-4E31-4424-B5F6-B4B8FBB42F3F

Q37151600-A49630D1-2C63-4E9C-938B-8B85AE6D80B1

Q37151600-A6682F1F-CC38-4025-8E0C-680FD6345D85

Q37151600-CCE0026B-B525-4BE2-BE36-F902D8F2621B

Q37151600-DAA48D66-C250-4D64-ACB6-DE942DFEE558

P2860

Q37151600-054A598B-543C-4CE7-9FFE-DCB729673358

Q37151600-054E4A5C-34A0-481F-AD67-A84FF20F6E91

Q37151600-0657C9AF-800D-448E-B6F6-1A82719A8748

Q37151600-07395031-5737-4220-847C-F7841FD991FB

Q37151600-09A355B5-561A-4C09-B183-59072EBA71D2

Q37151600-0B7E657A-4FA0-49B6-A5EF-23C4EE26A8AA

Q37151600-0B8C2F3D-03B6-40D3-AE93-F211FA45060A

Q37151600-3CEAC41F-729B-47D2-8978-3183D3BCE013

Q37151600-4110A56D-1A96-4CD1-9856-8DC2992FB856

Q37151600-6A6CA7EC-8FF2-4CA9-BA46-5E6056858DC6

P2888

Q37151600-4C17EE37-9E5F-496C-9FD8-055D54679957

P304

Q37151600-3FECF3B5-F728-4776-B9E9-91F9C50C44B1

P31

Q37151600-E53E5876-1583-47B7-B67B-D5039DF3F5FA

P356

Q37151600-4E154B94-3D42-43F9-8639-3FC1A922C408

P433

Q37151600-0B4E992C-4832-4047-9064-F851076C866F

P478

Q37151600-B3EC7297-CFE3-4AE2-8554-7E0EB36E926A

P50

Q37151600-A48CF468-A416-4597-8888-F11A38A12182

P577

Q37151600-18466031-8F56-4D57-B6FB-3AA25A9F6C9B

P6179

Q37151600-6EA80467-00D4-4D2C-9C34-DBEEB57D08AC

P698

Q37151600-CCF3F7A9-D88E-47CB-A50D-CEB92322A86D

P932

Q37151600-386F43F1-D2B3-460F-B108-4FA5D9EE3B91

P356

P1433

Acta Pharmacologica Sinica

P1476

Nuclear-targeting TAT-PEG-Asp8 ...... e drug-resistant colon cancer.

@en

P2093

Hui-Yuan Wang

http://www.w3.org/2001/XMLSchema#string

Meng Zhang

http://www.w3.org/2001/XMLSchema#string

Peng-Fei Zhao

http://www.w3.org/2001/XMLSchema#string

Ting-Ting Lin

http://www.w3.org/2001/XMLSchema#string

Wen-Yuan Zhang

http://www.w3.org/2001/XMLSchema#string

Yi-Si Tang

http://www.w3.org/2001/XMLSchema#string

Yong Xiong

http://www.w3.org/2001/XMLSchema#string

Yuan-Er Zeng

http://www.w3.org/2001/XMLSchema#string

Zhen-Zhen Pan

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

Nanoparticle therapeutics: an emerging treatment modality for cancer

Nanocarriers as an emerging platform for cancer therapy

On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity?

Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.

TAT-modified nanosilver for combating multidrug-resistant cancer.

Molecular mechanisms of drug resistance.

Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

Polymer-drug conjugates: recent development in clinical oncology

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.

P2888

P304

1110-1120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2016.48

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1000059343

http://www.w3.org/2001/XMLSchema#string

P698

27292613

http://www.w3.org/2001/XMLSchema#string

P932

4973383

http://www.w3.org/2001/XMLSchema#string